Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05209425
Other study ID # 2021-11-001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2022
Est. completion date April 30, 2023

Study information

Verified date September 2023
Source Factors Group of Nutritional Companies Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate plasma concentrations of Vitamin D (25-hydroxyvitamin D; 1,25-dihydroxyvitamin D) of different Vitamin D formulations in healthy volunteers at two concentrations. Pharmacokinetic parameters (Serum 25(OH)D and 1,25(OH)2D ng/ml) are compared with those of a regular Vitamin D formulation and a new (microencapsulated) LipoMicel Vitamin D formulation. The secondary objective of this study is to evaluate safety blood parameters- The following blood parameters (serum levels) are checked: Alkaline Phosphatase, ALT, AST, Bilirubin, CRP, Creatinine, GGT. In addition, mineral levels-such as calcium, magnesium and phosphorus, potassium and sodium-are measured before and at the end of the study.


Description:

Study Design: At least 40 healthy volunteers of both sexes in the age range 21-65 participate in a parallel, randomized blinded study conducted with different vitamin D3 products. Each treatment is administered orally per day at a total dose of 1000 UI and 2500 IU vitamin d3 (cholecalciferol), together with breakfast, over a period of 30 days. Participants are randomly divided into 4 groups (at least 10 per group): The first group receives regular Vitamin D (1000IU), the second receives microencapsulated D3 (1000IU), the third group receives regular Vitamin D (2500IU), the fourth receives microencapsulated D3 (2500 IU). Plasma concentrations (serum levels) of Vitamin D (25(OH)D and 1,25(OH)2D ng/ml are measured at baseline-before treatment start (day 0), during treatment (day 5, 10 and 15; one blood collection per day) and at end of treatment (day 30). After the end of supplementation, blood vitamin D concentrations are checked again at day 45 and day 60. The entire study session will span the course of 60 days. Participants are asked to attend 7 visits at LifeLabs to collect venous blood samples. Each Vitamin D treatment is consumed with a glass of water along with breakfast for a period of 30 days. Safety blood work is performed upon study enrolment, at the end of the Vitamin supplementation (day 30)- and at the end of the study (day 60) at Life Labs. The following blood parameters are checked and must be within normal ranges to participate the study: Alkaline Phosphatase, ALT, AST, Bilirubin, CRP, Creatinine, GGT. Mineral levels-such as calcium, magnesium and phosphorus-are measured before and at the end of the study (day 30). All participants must understand written and spoken English and give written informed consent before any study specific procedure will be carried out. All tested products are formulation manufactured by Factors Group.


Recruitment information / eligibility

Status Completed
Enrollment 37
Est. completion date April 30, 2023
Est. primary completion date April 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 65 Years
Eligibility Inclusion Criteria: - age between 21 and 65 years; avoid consumption of any additional food supplements containing vitamin D; avoid use of tanning beds or other artificial UVB sources. Participants must complete an online questionnaire on their medical history, weight, height, lifestyle (smoking, exercising etc.) and dietary habits relating to food rich in vitamin D, including other dietary supplementations. Exclusion Criteria: - use of vitamin D, calcium, magnesium, fish oil, or omega 3 fatty acids supplements; history of acute or chronic illness (such as gastrointestinal, liver and kidney disorders, osteoporosis …); pregnancy or lactation.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Vitamin D3
Participants are randomly divided into 4 groups. The first group receives regular Vitamin D3 (1000IU), the second receives microencapsulated D3 (1000IU), the third group receives regular Vitamin D3 (2500IU), the fourth receives microencapsulated D3 (2500 IU). Plasma concentrations of Vitamin D (D3, 25(OH)D3 and D2) are measured at baseline-before treatment start (day 0), during treatment (day 14) and at end of treatment (day 30). After the end of supplementation, blood vitamin D concentrations are checked again at day 45 and day 60.

Locations

Country Name City State
Canada Natural Factors Coquitlam British Columbia

Sponsors (1)

Lead Sponsor Collaborator
Factors Group of Nutritional Companies Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of Vitamin D serum level: change of 1,25-Dihydroxyvitamin D Venous blood samples are collected to measure concentrations of 1,25-Dihydroxyvitamin D at day 0 (before treatment), at day 5, 10, 15 (during treatment), at day 30 (end of treatment), at day 45 and 60 (after treatment).
Primary Evaluation of Vitamin D serum level: change of 25-Hydroxyvitamin D Venous blood samples are collected to measure concentrations of 25-Hydroxyvitamin D at day 0 (before treatment), at day 5, 10, 15 (during treatment), at day 30 (end of treatment), at day 45 and 60 (after treatment).
Secondary Safety blood work evaluation - change of aspartate aminotransferase (AST) Venous blood samples are collected to measure concentrations of AST at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment).
Secondary Safety blood work evaluation - change of alanine aminotransferase (ALT) Venous blood samples are collected to measure concentrations of ALT at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment).
Secondary Safety blood work evaluation - change of alkaline phosphatase Venous blood samples are collected to measure concentrations of alkaline phosphatase at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment).
Secondary Safety blood work evaluation - change of bilirubin Venous blood samples are collected to measure concentrations of total bilirubin at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment).
Secondary Safety blood work evaluation - change of gamma-glutamyl transferase (GGT) Venous blood samples are collected to measure concentrations of GGT at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment).
Secondary Safety blood work evaluation - change of creatinine Venous blood samples are collected to measure concentrations of creatinine at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment).
Secondary Safety blood work evaluation - change of C Reactive Protein (CRP) Venous blood samples are collected to measure concentrations of CRP at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment).
Secondary Safety blood work evaluation - change of mineral levels such as calcium Venous blood samples are collected to measure concentrations of calcium at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment).
Secondary Safety blood work evaluation - change of mineral levels such as magnesium Venous blood samples are collected to measure concentrations of magnesium at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment).
Secondary Safety blood work evaluation - change of mineral levels such as phosphate Venous blood samples are collected to measure concentrations of phosphate at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment).
Secondary Safety blood work evaluation - change of mineral levels such as sodium Venous blood samples are collected to measure concentrations of sodium at day 0 (before treatment), at day 30 (end of treatment), at day 60 (after treatment).
See also
  Status Clinical Trial Phase
Recruiting NCT05186194 - The Effect of Vitamin D and Calcium Supplementation on the Prevention of Stress Fractures. N/A
Recruiting NCT06101147 - Effect of Vitamin D Supplementation on Testosterone Level in Women With Polycystic Ovary Syndrome Phase 2
Completed NCT02904421 - 6 Years Study on Changes in Bone Quality, Bone Turnover and Curve Severity in AIS With and Without Calcium and Vit-D Supplementation
Completed NCT02092701 - Effects of Cholecalciferol Supplementation on Bone Health and Muscle Strength in Adults During Post-burn Period N/A
Completed NCT05748249 - Evaluation of the Efficacy of Vertistop® D and Vertistop® L in the Prevention of BPPV Recurrence Phase 1
Recruiting NCT04844957 - Correlation Between Vitamin D and Symptoms Severity of Autonomic Nervous Mediated Syncope Child and it 's RAAS Early Phase 1
Completed NCT05313477 - The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With TDF Phase 4
Completed NCT01170572 - Longitudinal Study of Patients Following Long Bone Fracture N/A
Not yet recruiting NCT01080950 - Vitamin D Zinc Fever N/A
Active, not recruiting NCT04564625 - Relationships Between Vitamin D and Orthopedic Trauma
Not yet recruiting NCT01992263 - Vitamin D Supplementation and TB N/A
Completed NCT00938600 - Antenatal Vitamin D3 Dose-finding and Safety Study Phase 1
Completed NCT04502667 - Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19 Phase 3
Completed NCT04535791 - Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers Phase 3
Recruiting NCT05448365 - Vitamin D, Epigallocatechin Gallate, D-chiro-inositol and Vitamin B6 in Uterine Fibroid Phase 3
Recruiting NCT03533010 - Preventing Curve Progression and the Need for Bracing in Adolescent Idiopathic Scoliosis With Calcium + Vitamin D Supplementation N/A
Recruiting NCT04404842 - Development of a Screening Tool for the Risk of Vitamin D Deficiency
Recruiting NCT05208827 - Vitamin D Supplementation for the Prevention of GDM Early Phase 1
Withdrawn NCT03073369 - Effect of Ergocalciferol on Iron Metabolism in Individuals With Chronic Kidney Disease Phase 4
Completed NCT02361827 - The Effect of Vitamin D on in Vitro Fertilization Outcome